CIP, Cancer Immunology Project

Forwarded from NIIMA, Network of Immunity in Infection, Malignancy and Autoimmunity

Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma

New paper by USERN interest groups

🌀Cutaneous squamous cell carcinoma (SCC) accounts for the second most commonly occurring non melanoma skin cancer.

🌀Metastatic and locally advanced cutaneous SCC have poor response to surgery or radiotherapy; however, systemic therapies can be an alternative option for patients that are not candidates for local therapies.

🌀The combination of PD1 inhibitors with other therapies such as radiation may increase the response in advanced cutaneous squamous cell carcinoma.

🌀Administration of PD1 inhibitors have shown higher response rates in tumors with high TMB compared to those with lower tumor mutation burden; However, other variables must be considered.

Source: https://doi.org/10.1080/14737140.2020.1812389

#Paper

@niima_usern
@cip_usern
@usern_net

www.tgoop.com/CIP_USERN/177

218 viewsAug 27, 2020 at 20:37

Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma

New paper by USERN interest groups

🌀Cutaneous squamous cell carcinoma (SCC) accounts for the second most commonly occurring non melanoma skin cancer.

🌀Metastatic and locally advanced cutaneous SCC have poor response to surgery or radiotherapy; however, systemic therapies can be an alternative option for patients that are not candidates for local therapies.

🌀The combination of PD1 inhibitors with other therapies such as radiation may increase the response in advanced cutaneous squamous cell carcinoma.

🌀Administration of PD1 inhibitors have shown higher response rates in tumors with high TMB compared to those with lower tumor mutation burden; However, other variables must be considered.

Source: https://doi.org/10.1080/14737140.2020.1812389

#Paper

@niima_usern
@cip_usern
@usern_net

BY CIP, Cancer Immunology Project